Q1 Earnings Estimate for DMAC Issued By HC Wainwright

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) – Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for DiaMedica Therapeutics in a report issued on Wednesday, March 19th. HC Wainwright analyst M. Caufield forecasts that the company will post earnings per share of ($0.18) for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for DiaMedica Therapeutics’ current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for DiaMedica Therapeutics’ Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.73) EPS, FY2026 earnings at ($0.93) EPS, FY2027 earnings at ($0.92) EPS, FY2028 earnings at ($0.46) EPS and FY2029 earnings at $0.06 EPS.

DiaMedica Therapeutics (NASDAQ:DMAC) last issued its earnings results on Monday, March 17th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.01).

DiaMedica Therapeutics Trading Down 3.1 %

NASDAQ DMAC opened at $4.98 on Friday. The firm has a market cap of $212.95 million, a price-to-earnings ratio of -8.89 and a beta of 1.52. The company has a 50 day moving average of $5.93 and a 200-day moving average of $5.12. DiaMedica Therapeutics has a 1-year low of $2.14 and a 1-year high of $6.82.

Institutional Investors Weigh In On DiaMedica Therapeutics

A number of institutional investors have recently modified their holdings of the business. Point72 Asia Singapore Pte. Ltd. acquired a new stake in DiaMedica Therapeutics in the 3rd quarter worth about $40,000. Balyasny Asset Management L.P. bought a new position in shares of DiaMedica Therapeutics during the fourth quarter worth approximately $79,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of DiaMedica Therapeutics in the fourth quarter valued at approximately $81,000. Raymond James Financial Inc. bought a new stake in shares of DiaMedica Therapeutics in the fourth quarter valued at approximately $83,000. Finally, Bank of Montreal Can bought a new stake in shares of DiaMedica Therapeutics in the fourth quarter valued at approximately $84,000. Institutional investors own 10.12% of the company’s stock.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.